Regulation of skeletal muscle plasticity by glycogen synthase kinase-3β: A potential target for the treatment of muscle wasting

Current Pharmaceutical Design

Volumn 19, Issue 18, 2013, Pages 3276-3298

  Verhees, Koen J P ^a   Pansters, Nicholas A M ^a   Schols, Annemie M W J ^a   Langen, Ramon C J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Glycogen synthase kinase 3 ; Muscle atrophy; Muscle plasticity; Regeneration; Signal transduction; Ubiquitin 26s proteasome

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; ATROGIN 1; AXIN; AZD 2858; BETA ARRESTIN 2; BETA CATENIN; BIP 135; CALPAIN; CALPASTATIN; CASEIN KINASE IALPHA; CASPASE 3; CT 20026; CYCLIN D1; DISHEVELLED 1; FRIZZLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK TRANSCRIPTION FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATION FACTOR 2; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; MUSCLE RING FINGER 1 PROTEIN; MYC PROTEIN; MYOSIN HEAVY CHAIN; PROTEIN KINASE B; TAU PROTEIN; TIDEGLUSIB; UNCLASSIFIED DRUG;

ALPHA HELIX; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; APOPTOSIS; AUTOPHAGOSOME; AUTOPHAGY; AUTOPHOSPHORYLATION; BETA SHEET; BONE MASS; CARBOXY TERMINAL SEQUENCE; CELL CYCLE PROGRESSION; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CELLULAR DISTRIBUTION; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG EFFICACY; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME INHIBITION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; IC 50; INSULIN SENSITIVITY; MUSCLE ATROPHY; MUSCLE GROWTH; MUSCLE MASS; MUSCLE REGENERATION; NEUROPROTECTION; NONHUMAN; OSTEOPOROSIS; OXIDATIVE STRESS; PHASE 2 CLINICAL TRIAL (TOPIC); PLASTICITY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REGULATORY MECHANISM; REVIEW; SATELLITE CELL; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TISSUE GROWTH; TISSUE METABOLISM; TRANSLATION INITIATION; WNT SIGNALING PATHWAY;

ANIMALS; DRUG DESIGN; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MOLECULAR TARGETED THERAPY; MUSCLE FIBERS, SKELETAL; MUSCLE, SKELETAL; MUSCULAR ATROPHY; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 84878823527     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319180011     Document Type: Review

References (380)

1. Sakuma K, Yamaguchi A. Sarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass. J Cachexia Sarcopenia Muscle 2012; 3: 77-94.
2. Anker SD, Ponikowski P, Varney S, et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet 1997; 349: 1050-3.
3. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1791-7.
4. Debigare R, Cote CH, Maltais F. Peripheral muscle wasting in chronic obstructive pulmonary disease. Clinical relevance and mechanisms. Am J Respir Crit Care Med 2001; 164: 1712-7.
5. Valdez H, Lederman MM. Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev 1997: 187-228.
6. Altomonte L, Zoli A, Mirone L, Scolieri P, Magaro M. Serum levels of interleukin-1b, tumour necrosis factor-a and interleukin-2 in rheumatoid arthritis. Correlation with disease activity. Clin Rheumatol 1992; 11: 202-5.
7. Roubenoff R, Roubenoff RA, Cannon JG, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994; 93: 2379-86.
8. Argiles JM, Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Med Res Rev 1999; 19: 223-48.
9. Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011; 12: 489-95.
10. Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 2005; 82: 53-9.
11. Goodman CA, Mayhew DL, Hornberger TA. Recent progress toward understanding the molecular mechanisms that regulate skeletal muscle mass. Cell Signal 2011; 23: 1896-906.
12. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3β from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980; 107: 519-27.
13. Rylatt DB, Aitken A, Bilham T, Condon GD, Embi N, Cohen P. Glycogen synthase from rabbit skeletal muscle. Amino acid sequence at the sites phosphorylated by glycogen synthase kinase-3β, and extension of the N-terminal sequence containing the site phosphorylated by phosphorylase kinase. Eur J Biochem 1980; 107: 529-37.
14. Ali A, Hoeflich KP, Woodgett JR. Glycogen synthase kinase-3β: properties, functions, and regulation. Chem Rev 2001; 101: 2527-40.
15. Kaidanovich-Beilin O, Woodgett JR. GSK-3β: Functional Insights from Cell Biology and Animal Models. Front Mol Neurosci 2011; 4: 40.
16. Phukan S, Babu VS, Kannoji A, Hariharan R, Balaji VN. GSK3beta: role in therapeutic landscape and development of modulators. Br J Pharmacol 2010; 160: 1-19.
17. Beurel E, Jope RS. The paradoxical proand anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Progress in neurobiology 2006; 79: 173-89.
18. Cohen P, Goedert M. GSK3 inhibitors: Development and their therapeutic potential. Nature Reviews, Drug Discovery 2004; 3: 479-87.
19. Cole A, Frame S, Cohen P. Further evidence that the tyrosine phosphorylation of glycogen synthase kinase-3β (GSK3) in mammalian cells is an autophosphorylation event. Biochem J 2004; 377: 249-55.
20. Dajani R, Fraser E, Roe SM, et al. Crystal structure of glycogen synthase kinase 3 beta: structural basis for phosphate-primed substrate specificity and autoinhibition. Cell 2001; 105: 721-32.
21. Hughes K, Nikolakaki E, Plyte SE, Totty NF, Woodgett JR. Modulation of the glycogen synthase kinase-3β family by tyrosine phosphorylation. EMBO J 1993; 12: 803-8.
22. Lochhead PA, Kinstrie R, Sibbet G, Rawjee T, Morrice N, Cleghon V. A chaperone-dependent GSK3beta transitional intermediate mediates activation-loop autophosphorylation. Mol Cell 2006; 24: 627-33.
23. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3β by insulin mediated by protein kinase B. Nature 1995; 378: 785-9.
24. Miura T, Miki T. GSK-3βbeta, a therapeutic target for cardiomyocyte protection. Circ J 2009; 73: 1184-92.
25. Cheng H, Woodgett J, Maamari M, Force T. Targeting GSK-3β family members in the heart: a very sharp double-edged sword. J Mol Cell Cardiol 2011; 51: 607-13.
26. Henriksen EJ. Dysregulation of glycogen synthase kinase-3β in skeletal muscle and the etiology of insulin resistance and type 2 diabetes. Curr Diabetes Rev 2010; 6: 285-93.
27. Embi N, Rylatt DB, Cohen P. Glycogen synthase kinase-3β from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur J Biochem 1980; 107: 519-27.
28. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J 2001; 359: 1-16.
29. Woodgett JR. Molecular cloning and expression of glycogen synthase kinase-3β/factor A. Embo J 1990; 9: 2431-8.
30. Woodgett JR. cDNA cloning and properties of glycogen synthase kinase-3β. Methods Enzymol 1991; 200: 564-77.
31. Plyte SE, Hughes K, Nikolakaki E, Pulverer BJ, Woodgett JR. Glycogen synthase kinase-3β: functions in oncogenesis and development. Biochim Biophys Acta 1992; 1114: 147-62.
32. Alon LT, Pietrokovski S, Barkan S, et al. Selective loss of glycogen synthase kinase-3βalpha in birds reveals distinct roles for GSK-3β isozymes in tau phosphorylation. FEBS Lett 2011; 585: 1158-62.
33. Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. Science 2004; 303: 1800-5.
34. Hanks SK, Quinn AM. Protein kinase catalytic domain sequence database: identification of conserved features of primary structure and classification of family members. Methods Enzymol 1991; 200: 38-62.
35. Hanks SK, Quinn AM, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 1988; 241: 42-52.
36. Taylor SS, Radzio-Andzelm E, Hunter T. How do protein kinases discriminate between serine/threonine and tyrosine? Structural insights from the insulin receptor protein-tyrosine kinase. Faseb J 1995; 9: 1255-66.
37. Hanks SK, Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. Faseb J 1995; 9: 576-96.
38. Hoeflich KP, Luo J, Rubie EA, Tsao MS, Jin O, Woodgett JR. Requirement for glycogen synthase kinase-3βbeta in cell survival and NF-kappaB activation. Nature 2000; 406: 86-90.
39. Doble BW, Patel S, Wood GA, Kockeritz LK, Woodgett JR. Functional redundancy of GSK-3βalpha and GSK-3βbeta in Wnt/betacatenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell 2007; 12: 957-71.
40. Ruel L, Bourouis M, Heitzler P, Pantesco V, Simpson P. Drosophila shaggy kinase and rat glycogen synthase kinase-3β have conserved activities and act downstream of Notch. Nature 1993; 362: 557-60.
41. Siegfried E, Chou TB, Perrimon N. Wingless signaling acts through zeste-white 3, the Drosophila homolog of glycogen synthase kinase-3β, to regulate engrailed and establish cell fate. Cell 1992; 71: 1167-79.
42. Gillespie JR, Ulici V, Dupuis H, et al. Deletion of glycogen synthase kinase-3βbeta in cartilage results in up-regulation of glycogen synthase kinase-3βalpha protein expression. Endocrinology 2011; 152: 1755-66.
43. Itoh S, Saito T, Hirata M, et al. GSK-3βalpha and GSK-3βbeta are involved in early stages of chondrocyte differentiation with functional redundancy through RelA phosphorylation. J Biol Chem 2012.
44. Liang MH, Chuang DM. Differential roles of glycogen synthase kinase-3β isoforms in the regulation of transcriptional activation. J Biol Chem 2006; 281: 30479-84.
45. Wang QM, Park IK, Fiol CJ, Roach PJ, DePaoli-Roach AA. Isoform differences in substrate recognition by glycogen synthase kinases 3 alpha and 3 beta in the phosphorylation of phosphatase inhibitor 2. Biochemistry 1994; 33: 143-7.
46. Kerkela R, Kockeritz L, Macaulay K, et al. Deletion of GSK-3βbeta in mice leads to hypertrophic cardiomyopathy secondary to cardiomyoblast hyperproliferation. J Clin Invest 2008; 118: 3609-18.
47. Force T, Woodgett JR. Unique and overlapping functions of GSK-3β isoforms in cell differentiation and proliferation and cardiovascular development. J Biol Chem 2009; 284: 9643-7.
48. Cho J, Rameshwar P, Sadoshima J. Distinct roles of glycogen synthase kinase (GSK)-3alpha and GSK-3βbeta in mediating cardiomyocyte differentiation in murine bone marrow-derived mesenchymal stem cells. J Biol Chem 2009; 284: 36647-58.
49. MacAulay K, Doble BW, Patel S, et al. Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab 2007; 6: 329-37.
50. Pearce NJ, Arch JR, Clapham JC, et al. Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3βbeta on a muscle-specific promoter. Metabolism 2004; 53: 1322-30.
51. McManus EJ, Sakamoto K, Armit LJ, et al. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. Embo J 2005; 24: 1571-83.
52. Patel S, Doble BW, MacAulay K, Sinclair EM, Drucker DJ, Woodgett JR. Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis and insulin action. Mol Cell Biol 2008; 28: 6314-28.
53. Doble BW, Woodgett JR. GSK-3β: tricks of the trade for a multitasking kinase. J Cell Sci 2003; 116: 1175-86.
54. Harwood AJ. Regulation of GSK-3β: a cellular multiprocessor. Cell 2001; 105: 821-4.
55. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3βbeta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12: 3499-511.
56. Gregory MA, Qi Y, Hann SR. Phosphorylation by glycogen synthase kinase-3β controls c-myc proteolysis and subnuclear localization. J Biol Chem 2003; 278: 51606-12.
57. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R. beta-catenin is a target for the ubiquitin-proteasome pathway. Embo J 1997; 16: 3797-804.
58. Zhou F, Zhang L, Wang A, et al. The association of GSK3 beta with E2F1 facilitates nerve growth factor-induced neural cell differentiation. J Biol Chem 2008; 283: 14506-15.
59. Mazanetz MP, Fischer PM. Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases. Nat Rev Drug Discov 2007; 6: 464-79.
60. Fiol CJ, Mahrenholz AM, Wang Y, Roeske RW, Roach PJ. Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J Biol Chem 1987; 262: 14042-8.
61. ter Haar E, Coll JT, Austen DA, Hsiao HM, Swenson L, Jain J. Structure of GSK3beta reveals a primed phosphorylation mechanism. Nat Struct Biol 2001; 8: 593-6.
62. Frame S, Cohen P, Biondi RM. A common phosphate binding site explains the unique substrate specificity of GSK3 and its inactivation by phosphorylation. Mol Cell 2001; 7: 1321-7.
63. Thomas GM, Frame S, Goedert M, Nathke I, Polakis P, Cohen P. A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and beta-catenin. FEBS Lett 1999; 458: 247-51.
64. Bax B, Carter PS, Lewis C, et al. The structure of phosphorylated GSK-3βbeta complexed with a peptide, FRATtide, that inhibits betacatenin phosphorylation. Structure 2001; 9: 1143-52.
65. Linding R, Jensen LJ, Ostheimer GJ, et al. Systematic discovery of in vivo phosphorylation networks. Cell 2007; 129: 1415-26.
66. Dugo L, Collin M, Thiemermann C. Glycogen synthase kinase 3beta as a target for the therapy of shock and inflammation. Shock 2007; 27: 113-23.
67. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3 beta in cellular signaling. Prog Neurobiol 2001; 65: 391-426.
68. Hurel SJ, Rochford JJ, Borthwick AC, et al. Insulin action in cultured human myoblasts: contribution of different signalling pathways to regulation of glycogen synthesis. Biochem J 1996; 320 (Pt 3): 871-7.
69. van Weeren PC, de Bruyn KM, de Vries-Smits AM, van Lint J, Burgering BM. Essential role for protein kinase B (PKB) in insulin-induced glycogen synthase kinase 3 inactivation. Characterization of dominant-negative mutant of PKB. J Biol Chem 1998; 273: 13150-6.
70. Cohen P, Frame S. The renaissance of GSK3. Nature Reviews, Molecular Cell Biology 2001; 2: 769-776.
71. Ilouz R, Pietrokovski S, Eisenstein M, Eldar-Finkelman H. New insights into the autoinhibition mechanism of glycogen synthase kinase-3βbeta. J Mol Biol 2008; 383: 999-1007.
72. Peyrollier K, Hajduch E, Blair AS, Hyde R, Hundal HS. L-leucine availability regulates phosphatidylinositol 3-kinase, p70 S6 kinase and glycogen synthase kinase-3β activity in L6 muscle cells: evidence for the involvement of the mammalian target of rapamycin (mTOR) pathway in the L-leucine-induced up-regulation of system A amino acid transport. Biochem J 2000; 350 Pt 2: 361-8.
73. Armstrong JL, Bonavaud SM, Toole BJ, Yeaman SJ. Regulation of glycogen synthesis by amino acids in cultured human muscle cells. J Biol Chem 2001; 276: 952-6.
74. Jope RS, Johnson GV. The glamour and gloom of glycogen synthase kinase-3β. Trends Biochem Sci 2004; 29: 95-102.
75. Tanji C, Yamamoto H, Yorioka N, Kohno N, Kikuchi K, Kikuchi A. A-kinase anchoring protein AKAP220 binds to glycogen synthase kinase-3βbeta (GSK-3βbeta) and mediates protein kinase A dependent inhibition of GSK-3βbeta. J Biol Chem 2002; 277: 36955-61.
76. Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS. Inhibitory phosphorylation of glycogen synthase kinase-3β (GSK-3β) in response to lithium. Evidence for autoregulation of GSK-3β. J Biol Chem 2003; 278: 33067-77.
77. Ivaska J, Nissinen L, Immonen N, Eriksson JE, Kahari VM, Heino J. Integrin alpha 2 beta 1 promotes activation of protein phosphatase 2A and dephosphorylation of Akt and glycogen synthase kinase 3 beta. Mol Cell Biol 2002; 22: 1352-9.
78. Buch I, Fishelovitch D, London N, Raveh B, Wolfson HJ, Nussinov R. Allosteric regulation of glycogen synthase kinase 3beta: a theoretical study. Biochemistry 2010; 49: 10890-901.
79. Murai H, Okazaki M, Kikuchi A. Tyrosine dephosphorylation of glycogen synthase kinase-3β is involved in its extracellular signaldependent inactivation. FEBS Lett 1996; 392: 153-60.
80. Shaw M, Cohen P, Alessi DR. Further evidence that the inhibition of glycogen synthase kinase-3βbeta by IGF-1 is mediated by PDK1/PKB-induced phosphorylation of Ser-9 and not by dephosphorylation of Tyr-216. FEBS Lett 1997; 416: 307-11.
81. Simon D, Benitez MJ, Gimenez-Cassina A, et al. Pharmacological inhibition of GSK-3β is not strictly correlated with a decrease in tyrosine phosphorylation of residues 216/279. J Neurosci Res 2008; 86: 668-74.
82. Bhat RV, Shanley J, Correll MP, et al. Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3βbeta in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci U S A 2000; 97: 11074-9.
83. Ding Q, Xia W, Liu JC, et al. Erk associates with and primes GSK-3βbeta for its inactivation resulting in upregulation of beta-catenin. Mol Cell 2005; 19: 159-70.
84. Thornton TM, Pedraza-Alva G, Deng B, et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science 2008; 320: 667-70.
85. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and betacatenin signalling: diseases and therapies. Nat Rev Genet 2004; 5: 691-701.
86. Wodarz A, Nusse R. Mechanisms of Wnt signaling in development. Annual review of cell and developmental biology 1998; 14: 59-88.
87. Huelsken J, Behrens J. The Wnt signalling pathway. J Cell Sci 2002; 115: 3977-8.
88. Liu C, Li Y, Semenov M, et al. Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 2002; 108: 837-47.
89. Tamai K, Semenov M, Kato Y, et al. LDL-receptor-related proteins in Wnt signal transduction. Nature 2000; 407: 530-5.
90. Li L, Yuan H, Weaver CD, et al. Axin and Frat1 interact with dvl and GSK, bridging Dvl to GSK in Wnt-mediated regulation of LEF-1. EMBO J 1999; 18: 4233-40.
91. Davidson G, Wu W, Shen J, et al. Casein kinase 1 gamma couples Wnt receptor activation to cytoplasmic signal transduction. Nature 2005; 438: 867-72.
92. Zeng X, Tamai K, Doble B, et al. A dual-kinase mechanism for Wnt co-receptor phosphorylation and activation. Nature 2005; 438: 873-7.
93. Liu X, Rubin JS, Kimmel AR. Rapid, Wnt-induced changes in GSK3beta associations that regulate beta-catenin stabilization are mediated by Galpha proteins. Curr Biol 2005; 15: 1989-97.
94. Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol 2009; 10: 468-77.
95. Novak A, Dedhar S. Signaling through beta-catenin and Lef/Tcf. Cell Mol Life Sci 1999; 56: 523-37.
96. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annual review of cell and developmental biology 2004; 20: 781-810.
97. Nusse R. Cell biology: relays at the membrane. Nature 2005; 438: 747-9.
98. Nelson WJ, Nusse R. Convergence of Wnt, beta-catenin, and cadherin pathways. Science 2004; 303: 1483-7.
99. Fraser E, Young N, Dajani R, et al. Identification of the Axin and Frat binding region of glycogen synthase kinase-3β. J Biol Chem 2002; 277: 2176-85.
100. Franca-Koh J, Yeo M, Fraser E, Young N, Dale TC. The regulation of glycogen synthase kinase-3β nuclear export by Frat/GBP. J Biol Chem 2002; 277: 43844-8.
101. Watcharasit P, Bijur GN, Zmijewski JW, et al. Direct, activating interaction between glycogen synthase kinase-3βbeta and p53 after DNA damage. Proc Natl Acad Sci U S A 2002; 99: 7951-5.
102. Watcharasit P, Bijur GN, Song L, Zhu J, Chen X, Jope RS. Glycogen synthase kinase-3βbeta (GSK3beta) binds to and promotes the actions of p53. J Biol Chem 2003; 278: 48872-9.
103. Bijur GN, Jope RS. Glycogen synthase kinase-3β beta is highly activated in nuclei and mitochondria. Neuroreport 2003; 14: 2415-9.
104. Azoulay-Alfaguter I, Yaffe Y, Licht-Murava A, et al. Distinct molecular regulation of glycogen synthase kinase-3βalpha isozyme controlled by its N-terminal region: functional role in calcium/calpain signaling. J Biol Chem 2011; 286: 13470-80.
105. Neal JW, Clipstone NA. Glycogen synthase kinase-3β inhibits the DNA binding activity of NFATc. J Biol Chem 2001; 276: 3666-73.
106. Ragano-Caracciolo M, Berlin WK, Miller MW, Hanover JA. Nuclear glycogen and glycogen synthase kinase 3. Biochem Biophys Res Commun 1998; 249: 422-7.
107. Alt JR, Cleveland JL, Hannink M, Diehl JA. Phosphorylationdependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 2000; 14: 3102-14.
108. Xavier IJ, Mercier PA, McLoughlin CM, Ali A, Woodgett JR, Ovsenek N. Glycogen synthase kinase 3beta negatively regulates both DNA-binding and transcriptional activities of heat shock factor 1. J Biol Chem 2000; 275: 29147-52.
109. Bijur GN, Jope RS. Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3β beta. J Biol Chem 2001; 276: 37436-42.
110. Haq S, Choukroun G, Kang ZB, et al. Glycogen synthase kinase-3βbeta is a negative regulator of cardiomyocyte hypertrophy. J Cell Biol 2000; 151: 117-30.
111. Ougolkov AV, Fernandez-Zapico ME, Bilim VN, Smyrk TC, Chari ST, Billadeau DD. Aberrant nuclear accumulation of glycogen synthase kinase-3βbeta in human pancreatic cancer: association with kinase activity and tumor dedifferentiation. Clin Cancer Res 2006; 12: 5074-81.
112. Mukai F, Ishiguro K, Sano Y, Fujita SC. Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. J Neurochem 2002; 81: 1073-83.
113. Fujimuro M, Wu FY, ApRhys C, et al. A novel viral mechanism for dysregulation of beta-catenin in Kaposi's sarcoma-associated herpesvirus latency. Nat Med 2003; 9: 300-6.
114. Goni-Oliver P, Lucas JJ, Avila J, Hernandez F. N-terminal cleavage of GSK-3β by calpain: a new form of GSK-3β regulation. J Biol Chem 2007; 282: 22406-13.
115. Goni-Oliver P, Avila J, Hernandez F. Calpain-mediated truncation of GSK-3β in post-mortem brain samples. J Neurosci Res 2009; 87: 1156-61.
116. De Sarno P, Bijur GN, Zmijewska AA, Li X, Jope RS. In vivo regulation of GSK3 phosphorylation by cholinergic and NMDA receptors. Neurobiol Aging 2006; 27: 413-22.
117. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002; 106: 1543-9.
118. Rouet-Benzineb P, Buhler JM, Dreyfus P, et al. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail 1999; 1: 337-52.
119. Kandasamy AD, Schulz R. Glycogen synthase kinase-3βbeta is activated by matrix metalloproteinase-2 mediated proteolysis in cardiomyoblasts. Cardiovasc Res 2009; 83: 698-706.
120. Klein PS, Melton DA. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 1996; 93: 8455-9.
121. Stambolic V, Ruel L, Woodgett JR. Lithium inhibits glycogen synthase kinase-3β activity and mimics wingless signalling in intact cells. Curr Biol 1996; 6: 1664-8.
122. Ryves WJ, Harwood AJ. Lithium inhibits glycogen synthase kinase-3β by competition for magnesium. Biochem Biophys Res Commun 2001; 280: 720-5.
123. Kirshenboim N, Plotkin B, Shlomo SB, Kaidanovich-Beilin O, Eldar-Finkelman H. Lithium-mediated phosphorylation of glycogen synthase kinase-3βbeta involves PI3 kinase-dependent activation of protein kinase C-alpha. J Mol Neurosci 2004; 24: 237-45.
124. Jope RS. Lithium and GSK-3β: one inhibitor, two inhibitory actions, multiple outcomes. Trends Pharmacol Sci 2003; 24: 441-3.
125. Evenson AR, Fareed MU, Menconi MJ, Mitchell JC, Hasselgren PO. GSK-3βbeta inhibitors reduce protein degradation in muscles from septic rats and in dexamethasone-treated myotubes. Int J Biochem Cell Biol 2005; 37: 2226-38.
126. Mora A, Sabio G, Risco AM, et al. Lithium blocks the PKB and GSK3 dephosphorylation induced by ceramide through protein phosphatase-2A. Cell Signal 2002; 14: 557-62.
127. Bertsch S, Lang CH, Vary TC. Inhibition of glycogen synthase kinase 3 [beta] activity with lithium in vitro attenuates sepsisinduced changes in muscle protein turnover. Shock 2011; 35: 266-74.
128. Dokken BB, Saengsirisuwan V, Kim JS, Teachey MK, Henriksen EJ. Oxidative stress-induced insulin resistance in rat skeletal muscle: role of glycogen synthase kinase-3β. Am J Physiol Endocrinol Metab 2008; 294: E615-21.
129. Jefferson LS, Fabian JR, Kimball SR. Glycogen synthase kinase-3β is the predominant insulin-regulated eukaryotic initiation factor 2B kinase in skeletal muscle. Int J Biochem Cell Biol 1999; 31: 191-200.
130. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000; 351: 95-105.
131. Phiel CJ, Klein PS. Molecular targets of lithium action. Annu Rev Pharmacol Toxicol 2001; 41: 789-813.
132. Birch NJ. Letter: Lithium and magnesium-dependent enzymes. Lancet 1974; 2: 965-6.
133. Ryves WJ, Dajani R, Pearl L, Harwood AJ. Glycogen synthase kinase-3β inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem Biophys Res Commun 2002; 290: 967-72.
134. Ilouz R, Kaidanovich O, Gurwitz D, Eldar-Finkelman H. Inhibition of glycogen synthase kinase-3βbeta by bivalent zinc ions: insight into the insulin-mimetic action of zinc. Biochem Biophys Res Commun 2002; 295: 102-6.
135. Eglen RM, Reisine T. The current status of drug discovery against the human kinome. Assay Drug Dev Technol 2009; 7: 22-43.
136. Traxler P, Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol Ther 1999; 82: 195-206.
137. Ring DB, Johnson KW, Henriksen EJ, et al. Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes 2003; 52: 588-95.
138. Coghlan MP, Culbert AA, Cross DA, et al. Selective small molecule inhibitors of glycogen synthase kinase-3β modulate glycogen metabolism and gene transcription. Chem Biol 2000; 7: 793-803.
139. Bain J, Plater L, Elliott M, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007; 408: 297-315.
140. Lee SC, Shin D, Cho JM, Ro S, Suh YG. Structure-activity relationship of the 7-hydroxy benzimidazole analogs as glycogen synthase kinase 3beta inhibitor. Bioorg Med Chem Lett 2012; 22: 1891-4.
141. Markuns JF, Wojtaszewski JF, Goodyear LJ. Insulin and exercise decrease glycogen synthase kinase-3β activity by different mechanisms in rat skeletal muscle. J Biol Chem 1999; 274: 24896-900.
142. van der Velden JL, Langen RC, Kelders MC, Wouters EF, Janssen-Heininger YM, Schols AM. Inhibition of glycogen synthase kinase-3βbeta activity is sufficient to stimulate myogenic differentiation. Am J Physiol Cell Physiol 2006; 290: C453-62.
143. Eldar-Finkelman H, Martinez A. GSK-3β Inhibitors: Preclinical and Clinical Focus on CNS. Front Mol Neurosci 2011; 4: 32.
144. Hinoi T, Yamamoto H, Kishida M, Takada S, Kishida S, Kikuchi A. Complex formation of adenomatous polyposis coli gene product and axin facilitates glycogen synthase kinase-3β beta-dependent phosphorylation of beta-catenin and down-regulates beta-catenin. J Biol Chem 2000; 275: 34399-406.
145. Hardt SE, Sadoshima J. Glycogen synthase kinase-3β beta: A novel regulator of cardiac hypertrophy and development. Circ Res 2002; 90: 1055-63.
146. Hu S, Begum AN, Jones MR, et al. GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis 2009; 33: 193-206.
147. Rosa AO, Egea J, Martinez A, Garcia AG, Lopez MG. Neuroprotective effect of the new thiadiazolidinone NP00111 against oxygen-glucose deprivation in rat hippocampal slices: implication of ERK1/2 and PPARgamma receptors. Exp Neurol 2008; 212: 93-9.
148. Martinez A, Alonso M, Castro A, Perez C, Moreno FJ. First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3βbeta) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J Med Chem 2002; 45: 1292-9.
149. Conde S, Perez DI, Martinez A, Perez C, Moreno FJ. Thienyl and phenyl alpha-halomethyl ketones: new inhibitors of glycogen synthase kinase (GSK-3βbeta) from a library of compound searching. J Med Chem 2003; 46: 4631-3.
150. Perez DI, Conde S, Perez C, et al. Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools. Bioorg Med Chem 2009; 17: 6914-25.
151. Perez DI, Palomo V, Perez C, et al. Switching reversibility to irreversibility in glycogen synthase kinase 3 inhibitors: clues for specific design of new compounds. J Med Chem 2011; 54: 4042-56.
152. Eldar-Finkelman H, Eisenstein M. Peptide inhibitors targeting protein kinases. Curr Pharm Des 2009; 15: 2463-70.
153. Eldar-Finkelman H, Licht-Murava A, Pietrokovski S, Eisenstein M. Substrate competitive GSK-3β inhibitors strategy and implications. Biochim Biophys Acta 2010; 1804: 598-603.
154. Plotkin B, Kaidanovich O, Talior I, Eldar-Finkelman H. Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3β. J Pharmacol Exp Ther 2003; 305: 974-80.
155. Woodgett JR, Cohen P. Multisite phosphorylation of glycogen synthase. Molecular basis for the substrate specificity of glycogen synthase kinase-3β and casein kinase-II (glycogen synthase kinase-5). Biochim Biophys Acta 1984; 788: 339-47.
156. Schakman O, Kalista S, Bertrand L, et al. Role of Akt/GSK-3β{beta}/{beta}-catenin transduction pathway in the muscle antiatrophy action of Insulin-like growth factor (IGF)-I in glucocorticoid-treated rats. Endocrinology 2008.
157. Schakman O, Gilson H, de Coninck V, et al. Insulin-like growth factor-I gene transfer by electroporation prevents skeletal muscle atrophy in glucocorticoid-treated rats. Endocrinology 2005; 146: 1789-97.
158. Vyas DR, Spangenburg EE, Abraha TW, Childs TE, Booth FW. GSK-3βbeta negatively regulates skeletal myotube hypertrophy. Am J Physiol Cell Physiol 2002; 283: C545-51.
159. Kandarian SC, Jackman RW. Intracellular signaling during skeletal muscle atrophy. Muscle Nerve 2006; 33: 155-65.
160. Bodine SC, Stitt TN, Gonzalez M, et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo. Nat Cell Biol 2001; 3: 1014-9.
161. Dupont-Versteegden EE. Apoptosis in skeletal muscle and its relevance to atrophy. World journal of gastroenterology: WJG 2006; 12: 7463-6.
162. Wing SS, Lecker SH, Jagoe RT. Proteolysis in illness-associated skeletal muscle atrophy: from pathways to networks. Crit Rev Clin Lab Sci 2011; 48: 49-70.
163. Sandri M. New findings of lysosomal proteolysis in skeletal muscle. Current opinion in clinical nutrition and metabolic care 2011; 14: 223-9.
164. Smith IJ, Lecker SH, Hasselgren PO. Calpain activity and muscle wasting in sepsis. American journal of physiology. Endocrinology and metabolism 2008; 295: E762-71.
165. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008; 451: 1069-75.
166. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132: 27-42.
167. Clarke BA, Drujan D, Willis MS, et al. The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab 2007; 6: 376-85.
168. Cohen S, Brault JJ, Gygi SP, et al. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol 2009; 185: 1083-95.
169. Fielitz J, Kim MS, Shelton JM, et al. Myosin accumulation and striated muscle myopathy result from the loss of muscle RING finger 1 and 3. J Clin Invest 2007; 117: 2486-95.
170. Solomon V, Goldberg AL. Importance of the ATP-ubiquitinproteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts. J Biol Chem 1996; 271: 26690-7.
171. Braun T, Gautel M. Transcriptional mechanisms regulating skeletal muscle differentiation, growth and homeostasis. Nat Rev Mol Cell Biol 2011; 12: 349-61.
172. Hollway G, Currie P. Vertebrate myotome development. Birth Defects Res C Embryo Today 2005; 75: 172-9.
173. Mauro A. Satellite cell of skeletal muscle fibers. J Biophys Biochem Cytol 1961; 9: 493-5.
174. Morgan JE, Partridge TA. Muscle satellite cells. Int J Biochem Cell Biol 2003; 35: 1151-6.
175. Pallafacchina G, Blaauw B, Schiaffino S. Role of satellite cells in muscle growth and maintenance of muscle mass. Nutr Metab Cardiovasc Dis 2012.
176. Allen DL, Roy RR, Edgerton VR. Myonuclear domains in muscle adaptation and disease. Muscle Nerve 1999; 22: 1350-60.
177. Blaauw B, Canato M, Agatea L, et al. Inducible activation of Akt increases skeletal muscle mass and force without satellite cell activation. FASEB J 2009; 23: 3896-905.
178. Van der Meer SF, Jaspers RT, Degens H. Is the myonuclear domain size fixed? J Musculoskelet Neuronal Interact 2011; 11: 286-97.
179. Gundersen K, Bruusgaard JC. Nuclear domains during muscle atrophy: nuclei lost or paradigm lost? The Journal of physiology 2008; 586: 2675-81.
180. Dirks A, Leeuwenburgh C. Apoptosis in skeletal muscle with aging. Am J Physiol Regul Integr Comp Physiol 2002; 282: R519-27.
181. Dirks-Naylor AJ, Lennon-Edwards S. Cellular and molecular mechanisms of apoptosis in age-related muscle atrophy. Curr Aging Sci 2011; 4: 269-78.
182. Alway SE, Siu PM. Nuclear apoptosis contributes to sarcopenia. Exerc Sport Sci Rev 2008; 36: 51-7.
183. Siu PM. Muscle apoptotic response to denervation, disuse, and aging. Med Sci Sports Exerc 2009; 41: 1876-86.
184. Yasuhara S, Perez ME, Kanakubo E, et al. Skeletal muscle apoptosis after burns is associated with activation of proapoptotic signals. Am J Physiol Endocrinol Metab 2000; 279: E1114-21.
185. Siu PM, Alway SE. Response and adaptation of skeletal muscle to denervation stress: the role of apoptosis in muscle loss. Front Biosci 2009; 14: 432-52.
186. Allen DL, Linderman JK, Roy RR, et al. Apoptosis: a mechanism contributing to remodeling of skeletal muscle in response to hindlimb unweighting. Am J Physiol 1997; 273: C579-87.
187. Belizario JE, Lorite MJ, Tisdale MJ. Cleavage of caspases-1,-3,-6,-8 and-9 substrates by proteases in skeletal muscles from mice undergoing cancer cachexia. Br J Cancer 2001; 84: 1135-40.
188. Fanzani A, Conraads VM, Penna F, Martinet W. Molecular and cellular mechanisms of skeletal muscle atrophy: an update. J Cachexia Sarcopenia Muscle 2012.
189. Relaix F, Zammit PS. Satellite cells are essential for skeletal muscle regeneration: the cell on the edge returns centre stage. Development 2012; 139: 2845-56.
190. Yusuf F, Brand-Saberi B. Myogenesis and muscle regeneration. Histochemistry and cell biology 2012; 138: 187-99.
191. Aziz A, Sebastian S, Dilworth FJ. The origin and fate of muscle satellite cells. Stem Cell Rev 2012; 8: 609-22.
192. Salani S, Donadoni C, Rizzo F, Bresolin N, Comi GP, Corti S. Generation of skeletal muscle cells from embryonic and induced pluripotent stem cells as an in vitro model and for therapy of muscular dystrophies. J Cell Mol Med 2012; 16: 1353-64.
193. Kimball SR, Jefferson LS. Control of translation initiation through integration of signals generated by hormones, nutrients, and exercise. J Biol Chem 2010; 285: 29027-32.
194. Welsh GI, Proud CG. Glycogen synthase kinase-3β is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem J 1993; 294 (Pt 3): 625-9.
195. Welsh GI, Miller CM, Loughlin AJ, Price NT, Proud CG. Regulation of eukaryotic initiation factor eIF2B: glycogen synthase kinase-3β phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin. FEBS Lett 1998; 421: 125-30.
196. Clemmons DR. Role of IGF-I in skeletal muscle mass maintenance. Trends Endocrinol Metab 2009; 20: 349-56.
197. Wu M, Falasca M, Blough ER. Akt/protein kinase B in skeletal muscle physiology and pathology. J Cell Physiol 2010; 226: 29-36.
198. Lai KM, Gonzalez M, Poueymirou WT, et al. Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy. Mol Cell Biol 2004; 24: 9295-304.
199. Peng XD, Xu PZ, Chen ML, et al. Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone development, and impeded adipogenesis in mice lacking Akt1 and Akt2. Genes Dev 2003; 17: 1352-65.
200. Burgering BM, Coffer PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 1995; 376: 599-602.
201. Alessi DR, Cohen P. Mechanism of activation and function of protein kinase B. Curr Opin Genet Dev 1998; 8: 55-62.
202. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-101.
203. Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF-1. Embo J 1996; 15: 6541-51.
204. Jacinto E, Facchinetti V, Liu D, et al. SIN1/MIP1 maintains rictormTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006; 127: 125-37.
205. Proud CG. Regulation of protein synthesis by insulin. Biochem Soc Trans 2006; 34: 213-6.
206. Glass DJ. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 2005; 37: 1974-84.
207. Inoki K, Ouyang H, Zhu T, et al. TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell 2006; 126: 955-68.
208. Eldar-Finkelman H, Krebs EG. Phosphorylation of insulin receptor substrate 1 by glycogen synthase kinase 3 impairs insulin action. Proc Natl Acad Sci U S A 1997; 94: 9660-4.
209. Waraich RS, Weigert C, Kalbacher H, et al. Phosphorylation of Ser357 of rat insulin receptor substrate-1 mediates adverse effects of protein kinase C-delta on insulin action in skeletal muscle cells. J Biol Chem 2008; 283: 11226-33.
210. Liberman Z, Plotkin B, Tennenbaum T, Eldar-Finkelman H. Coordinated phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3β and protein kinase C betaII in the diabetic fat tissue. Am J Physiol Endocrinol Metab 2008; 294: E1169-77.
211. Kelly GM, Buckley DA, Kiely PA, Adams DR, O'Connor R. Serine Phosphorylation of the Insulin-like Growth Factor I (IGF-1) Receptor C-terminal Tail Restrains Kinase Activity and Cell Growth. J Biol Chem 2012; 287: 28180-94.
212. Lu Y, Muller M, Smith D, et al. Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling. Oncogene 2011; 30: 4567-77.
213. Michael A, Haq S, Chen X, et al. Glycogen synthase kinase-3βbeta regulates growth, calcium homeostasis, and diastolic function in the heart. J Biol Chem 2004; 279: 21383-93.
214. Rommel C, Bodine SC, Clarke BA, et al. Mediation of IGF-1induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. Nat Cell Biol 2001; 3: 1009-13.
215. He X, Saint-Jeannet JP, Woodgett JR, Varmus HE, Dawid IB. Glycogen synthase kinase-3β and dorsoventral patterning in Xenopus embryos. Nature 1995; 374: 617-22.
216. Fang CH, Li BG, James JH, et al. Protein breakdown in muscle from burned rats is blocked by insulin-like growth factor i and glycogen synthase kinase-3βbeta inhibitors. Endocrinology 2005; 146: 3141-9.
217. Fang CH, Li B, James JH, et al. GSK-3βbeta activity is increased in skeletal muscle after burn injury in rats. Am J Physiol Regul Integr Comp Physiol 2007; 293: R1545-51.
218. Vary TC, Deiter G, Kimball SR. Phosphorylation of eukaryotic initiation factor eIF2Bepsilon in skeletal muscle during sepsis. Am J Physiol Endocrinol Metab 2002; 283: E1032-9.
219. Sugita H, Kaneki M, Sugita M, Yasukawa T, Yasuhara S, Martyn JA. Burn injury impairs insulin-stimulated Akt/PKB activation in skeletal muscle. Am J Physiol Endocrinol Metab 2005; 288: E585-91.
220. Lecker SH, Goldberg AL, Mitch WE. Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol 2006; 17: 1807-19.
221. Hasselgren PO. Glucocorticoids and muscle catabolism. Curr Opin Clin Nutr Metab Care 1999; 2: 201-5.
222. Li BG, Hasselgren PO, Fang CH, Warden GD. Insulin-like growth factor-I blocks dexamethasone-induced protein degradation in cultured myotubes by inhibiting multiple proteolytic pathways: 2002 ABA paper. J Burn Care Rehabil 2004; 25: 112-8.
223. Li BG, Hasselgren PO, Fang CH. Insulin-like growth factor-I inhibits dexamethasone-induced proteolysis in cultured L6 myotubes through PI3K/Akt/GSK-3βbeta and PI3K/Akt/mTOR-dependent mechanisms. Int J Biochem Cell Biol 2005; 37: 2207-16.
224. Jackman RW, Kandarian SC. The molecular basis of skeletal muscle atrophy. Am J Physiol Cell Physiol 2004; 287: C834-43.
225. Jagoe RT, Lecker SH, Gomes M, Goldberg AL. Patterns of gene expression in atrophying skeletal muscles: response to food deprivation. FASEB J 2002; 16: 1697-712.
226. Schwartz AL, Ciechanover A. Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. Annu Rev Pharmacol Toxicol 2009; 49: 73-96.
227. Ciechanover A, Orian A, Schwartz AL. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 2000; 22: 442-51.
228. Sacheck JM, Hyatt JP, Raffaello A, et al. Rapid disuse and denervation atrophy involve transcriptional changes similar to those of muscle wasting during systemic diseases. FASEB J 2007; 21: 140-55.
229. Wray CJ, Mammen JM, Hershko DD, Hasselgren PO. Sepsis upregulates the gene expression of multiple ubiquitin ligases in skeletal muscle. Int J Biochem Cell Biol 2003; 35: 698-705.
230. Bodine SC, Latres E, Baumhueter S, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science 2001; 294: 1704-8.
231. Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A 2001; 98: 14440-5.
232. Zhao TJ, Yan YB, Liu Y, Zhou HM. The generation of the oxidized form of creatine kinase is a negative regulation on muscle creatine kinase. J Biol Chem 2007; 282: 12022-9.
233. Lagirand-Cantaloube J, Cornille K, Csibi A, Batonnet-Pichon S, Leibovitch MP, Leibovitch SA. Inhibition of atrogin-1/MAFbx mediated MyoD proteolysis prevents skeletal muscle atrophy in vivo. PLoS One 2009; 4: e4973.
234. Wang L, Luo GJ, Wang JJ, Hasselgren PO. Dexamethasone stimulates proteasome-and calcium-dependent proteolysis in cultured L6 myotubes. Shock 1998; 10: 298-306.
235. Sandri M, Sandri C, Gilbert A, Skurk C, et al. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell 2004; 117: 399-412.
236. Shim M, Smart RC. Lithium stabilizes the CCAAT/enhancerbinding protein alpha (C/EBPalpha) through a glycogen synthase kinase 3 (GSK3)-independent pathway involving direct inhibition of proteasomal activity. J Biol Chem 2003; 278: 19674-81.
237. Verhees KJ, Schols AM, Kelders MC, et al. Glycogen synthase kinase-3βbeta is required for the induction of skeletal muscle atrophy. Am J Physiol Cell Physiol 2011; 301: C995-C1007.
238. Ravikumar B, Sarkar S, Davies JE, et al. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev 2010; 90: 1383-435.
239. Sandri M. Autophagy in health and disease. 3. Involvement of autophagy in muscle atrophy. Am J Physiol Cell Physiol 2010; 298: C1291-7.
240. Schiaffino S, Hanzlikova V. Studies on the effect of denervation in developing muscle. II. The lysosomal system. J Ultrastruct Res 1972; 39: 1-14.
241. Furuno K, Goodman MN, Goldberg AL. Role of different proteolytic systems in the degradation of muscle proteins during denervation atrophy. J Biol Chem 1990; 265: 8550-7.
242. Masiero E, Agatea L, Mammucari C, et al. Autophagy is required to maintain muscle mass. Cell Metab 2009; 10: 507-15.
243. Mizushima N, Yamamoto A, Matsui M, Yoshimori T, Ohsumi Y. In vivo analysis of autophagy in response to nutrient starvation using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol Cell 2004; 15: 1101-11.
244. Aucello M, Dobrowolny G, Musaro A. Localized accumulation of oxidative stress causes muscle atrophy through activation of an autophagic pathway. Autophagy 2009; 5: 527-9.
245. Yang J, Takahashi Y, Cheng E, et al. GSK-3βbeta promotes cell survival by modulating Bif-1-dependent autophagy and cell death. J Cell Sci 2010; 123: 861-70.
246. Wang SH, Shih YL, Kuo TC, Ko WC, Shih CM. Cadmium toxicity toward autophagy through ROS-activated GSK-3βbeta in mesangial cells. Toxicol Sci 2009; 108: 124-31.
247. Sarkar S, Krishna G, Imarisio S, Saiki S, O'Kane CJ, Rubinsztein DC. A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 2008; 17: 170-8.
248. Lin SY, Li TY, Liu Q, et al. GSK3-TIP60-ULK1 signaling pathway links growth factor deprivation to autophagy. Science 2012; 336: 477-81.
249. Korolchuk VI, Menzies FM, Rubinsztein DC. Mechanisms of cross-talk between the ubiquitin-proteasome and autophagylysosome systems. FEBS Lett 2010; 584: 1393-8.
250. Pandey UB, Nie Z, Batlevi Y, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007; 447: 859-63.
251. Ding WX, Ni HM, Gao W, et al. Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability. Am J Pathol 2007; 171: 513-24.
252. Klionsky DJ. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat Rev Mol Cell Biol 2007; 8: 931-7.
253. Mammucari C, Milan G, Romanello V, et al. FoxO3 controls autophagy in skeletal muscle in vivo. Cell Metab 2007; 6: 458-71.
254. Zhao J, Brault JJ, Schild A, et al. FoxO3 coordinately activates protein degradation by the autophagic/lysosomal and proteasomal pathways in atrophying muscle cells. Cell Metab 2007; 6: 472-83.
255. Solomon V, Lecker SH, Goldberg AL. The N-end rule pathway catalyzes a major fraction of the protein degradation in skeletal muscle. J Biol Chem 1998; 273: 25216-22.
256. Williams AB, Decourten-Myers GM, Fischer JE, Luo G, Sun X, Hasselgren PO. Sepsis stimulates release of myofilaments in skeletal muscle by a calcium-dependent mechanism. Faseb J 1999; 13: 1435-43.
257. Hong DH, Forsberg NE. Effects of dexamethasone on protein degradation and protease gene expression in rat L8 myotube cultures. Mol Cell Endocrinol 1995; 108: 199-209.
258. Bartoli M, Richard I. Calpains in muscle wasting. Int J Biochem Cell Biol 2005; 37: 2115-33.
259. Huang J, Forsberg NE. Role of calpain in skeletal-muscle protein degradation. Proc Natl Acad Sci U S A 1998; 95: 12100-5.
260. Goll DE, Thompson VF, Li H, Wei W, Cong J. The calpain system. Physiol Rev 2003; 83: 731-801.
261. Haddad F, Roy RR, Zhong H, Edgerton VR, Baldwin KM. Atrophy responses to muscle inactivity. II. Molecular markers of protein deficits. J Appl Physiol 2003; 95: 791-802.
262. Tang H, Cheung WM, Ip FC, Ip NY. Identification and characterization of differentially expressed genes in denervated muscle. Mol Cell Neurosci 2000; 16: 127-40.
263. Voisin L, Breuille D, Combaret L, et al. Muscle wasting in a rat model of long-lasting sepsis results from the activation of lysosomal, Ca2+-activated, and ubiquitin-proteasome proteolytic pathways. J Clin Invest 1996; 97: 1610-7.
264. Whitehouse AS, Smith HJ, Drake JL, Tisdale MJ. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res 2001; 61: 3604-9.
265. Badalamente MA, Stracher A. Delay of muscle degeneration and necrosis in mdx mice by calpain inhibition. Muscle Nerve 2000; 23: 106-11.
266. Donkor IO. A survey of calpain inhibitors. Curr Med Chem 2000; 7: 1171-88.
267. Tidball JG, Spencer MJ. Expression of a calpastatin transgene slows muscle wasting and obviates changes in myosin isoform expression during murine muscle disuse. J Physiol 2002; 545: 819-28.
268. Fareed MU, Evenson AR, Wei W, et al. Treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expression. Am J Physiol Regul Integr Comp Physiol 2006; 290: R1589-97.
269. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5: 897-907.
270. Du J, Wang X, Miereles C, et al. Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest 2004; 113: 115-23.
271. Plant PJ, Bain JR, Correa JE, Woo M, Batt J. Absence of caspase-3 protects against denervation-induced skeletal muscle atrophy. J Appl Physiol 2009; 107: 224-34.
272. Smith IJ, Dodd SL. Calpain activation causes a proteasome-dependent increase in protein degradation and inhibits the Akt signalling pathway in rat diaphragm muscle. Exp Physiol 2007; 92: 561-73.
273. Nader GA. Molecular determinants of skeletal muscle mass: getting the AKT together. Int J Biochem Cell Biol 2005; 37: 1985-96.
274. Stitt TN, Drujan D, Clarke BA, et al. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell 2004; 14: 395-403.
275. Lang CH, Frost RA. Endotoxin disrupts the leucine-signaling pathway involving phosphorylation of mTOR, 4E-BP1, and S6K1 in skeletal muscle. J Cell Physiol 2005; 203: 144-55.
276. Liu ZQ, Kunimatsu M, Yang JP, Ozaki Y, Sasaki M, Okamoto T. Proteolytic processing of nuclear factor kappa B by calpain in vitro. FEBS Lett 1996; 385: 109-13.
277. Wei W, Yang H, Cao P, et al. Degradation of C/EBPbeta in cultured myotubes is calpain-dependent. J Cell Physiol 2006; 208: 386-98.
278. Oda A, Wakao H, Fujita H. Calpain is a signal transducer and activator of transcription (STAT) 3 and STAT5 protease. Blood 2002; 99: 1850-2.
279. Ebert SM, Dyle MC, Kunkel SD, et al. Stress-induced Skeletal Muscle Gadd45a Expression Reprograms Myonuclei and Causes Muscle Atrophy. J Biol Chem 2012; 287: 27290-301.
280. Ebert SM, Monteys AM, Fox DK, Bongers KS, Shields BE, Malmberg SE, Davidson BL, Suneja M, Adams CM. The transcription factor ATF4 promotes skeletal myofiber atrophy during fasting. Mol Endocrinol 2010; 24: 790-9.
281. King TD, Bijur GN, Jope RS. Caspase-3 activation induced by inhibition of mitochondrial complex I is facilitated by glycogen synthase kinase-3βbeta and attenuated by lithium. Brain Res 2001; 919: 106-14.
282. King TD, Jope RS. Inhibition of glycogen synthase kinase-3β protects cells from intrinsic but not extrinsic oxidative stress. Neuroreport 2005; 16: 597-601.
283. Bhat RV, Leonov S, Luthman J, Scott CW, Lee CM. Interactions between GSK3beta and caspase signalling pathways during NGF deprivation induced cell death. J Alzheimers Dis 2002; 4: 291-301.
284. Hildesheim J, Belova GI, Tyner SD, Zhou X, Vardanian L, Fornace AJ, Jr. Gadd45a regulates matrix metalloproteinases by suppressing DeltaNp63alpha and beta-catenin via p38 MAP kinase and APC complex activation. Oncogene 2004; 23: 1829-37.
285. Li Y, Gazdoiu S, Pan ZQ, Fuchs SY. Stability of homologue of Slimb F-box protein is regulated by availability of its substrate. J Biol Chem 2004; 279: 11074-80.
286. Wang XH, Zhang L, Mitch WE, LeDoux JM, Hu J, Du J. Caspase-3 cleaves specific 19 S proteasome subunits in skeletal muscle stimulating proteasome activity. J Biol Chem 2010; 285: 21249-57.
287. Latres E, Amini AR, Amini AA, et al. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. J Biol Chem 2005; 280: 2737-44.
288. Lecker SH, Solomon V, Mitch WE, Goldberg AL. Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states. J Nutr 1999; 129: 227S-237S.
289. Wing SS, Goldberg AL. Glucocorticoids activate the ATPubiquitin-dependent proteolytic system in skeletal muscle during fasting. Am J Physiol 1993; 264: E668-76.
290. Waddell DS, Baehr LM, van den Brandt J, et al. The glucocorticoid receptor and FOXO1 synergistically activate the skeletal muscle atrophy-associated MuRF1 gene. Am J Physiol Endocrinol Metab 2008; 295: E785-97.
291. Hu Z, Wang H, Lee IH, Du J, Mitch WE. Endogenous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J Clin Invest 2009; 119: 3059-69.
292. Menconi M, Fareed M, O'Neal P, Poylin V, Wei W, Hasselgren PO. Role of glucocorticoids in the molecular regulation of muscle wasting. Crit Care Med 2007; 35: S602-8.
293. Schakman O, Gilson H, Thissen JP. Mechanisms of glucocorticoidinduced myopathy. J Endocrinol 2008; 197: 1-10.
294. Ueki K, Fruman DA, Brachmann SM, Tseng YH, Cantley LC, Kahn CR. Molecular balance between the regulatory and catalytic subunits of phosphoinositide 3-kinase regulates cell signaling and survival. Mol Cell Biol 2002; 22: 965-77.
295. Li YH, Fan J, Lang CH. Differential role of glucocorticoids in mediating endotoxin-induced changes in IGF-I and IGFBP-1. Am J Physiol 1997; 272: R1990-7.
296. Kumari R, Willing LB, Jefferson LS, Simpson IA, Kimball SR. REDD1 (regulated in development and DNA damage response 1) expression in skeletal muscle as a surrogate biomarker of the efficiency of glucocorticoid receptor blockade. Biochem Biophys Res Commun 2011; 412: 644-7.
297. Shah OJ, Kimball SR, Jefferson LS. Glucocorticoids abate p70(S6k) and eIF4E function in L6 skeletal myoblasts. Am J Physiol Endocrinol Metab 2000; 279: E74-82.
298. Shah OJ, Kimball SR, Jefferson LS. Acute attenuation of translation initiation and protein synthesis by glucocorticoids in skeletal muscle. Am J Physiol Endocrinol Metab 2000; 278: E76-82.
299. Shimizu N, Yoshikawa N, Ito N, et al. Crosstalk between glucocorticoid receptor and nutritional sensor mTOR in skeletal muscle. Cell Metab 2011; 13: 170-82.
300. Galliher-Beckley AJ, Williams JG, Collins JB, Cidlowski JA. Glycogen synthase kinase 3beta-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles. Mol Cell Biol 2008; 28: 7309-22.
301. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-6.
302. Earnshaw WC, Martins LM, Kaufmann SH. Mammalian caspases: structure, activation, substrates, and functions during apoptosis. Annual review of biochemistry 1999; 68: 383-424.
303. Song L, De Sarno P, Jope RS. Central role of glycogen synthase kinase-3βbeta in endoplasmic reticulum stress-induced caspase-3 activation. J Biol Chem 2002; 277: 44701-8.
304. Mottet D, Dumont V, Deccache Y, et al. Regulation of hypoxiainducible factor-1alpha protein level during hypoxic conditions by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase. 3beta pathway in HepG2 cells. The Journal of biological chemistry 2003; 278: 31277-85.
305. Linseman DA, Butts BD, Precht TA, et al. Glycogen synthase kinase-3βbeta phosphorylates Bax and promotes its mitochondrial localization during neuronal apoptosis. The Journal of neuroscience: the official journal of the Society for Neuroscience 2004; 24: 9993-10002.
306. Hongisto V, Smeds N, Brecht S, Herdegen T, Courtney MJ, Coffey ET. Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3. Molecular and cellular biology 2003; 23: 6027-36.
307. Maurer U, Charvet C, Wagman AS, Dejardin E, Green DR. Glycogen synthase kinase-3β regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL-1. Molecular cell 2006; 21: 749-60.
308. Alvarez AR, Godoy JA, Mullendorff K, Olivares GH, Bronfman M, Inestrosa NC. Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. Experimental cell research 2004; 297: 186-96.
309. Rao R, Hao CM, Breyer MD. Hypertonic stress activates glycogen synthase kinase 3beta-mediated apoptosis of renal medullary interstitial cells, suppressing an NFkappaB-driven cyclooxygenase-2-dependent survival pathway. The Journal of biological chemistry 2004; 279: 3949-55.
310. Schwabe RF, Brenner DA. Role of glycogen synthase kinase-3β in TNF-alpha-induced NF-kappaB activation and apoptosis in hepatocytes. American journal of physiology. Gastrointestinal and liver physiology 2002; 283: G204-11.
311. Liao X, Zhang L, Thrasher JB, Du J, Li B. Glycogen synthase kinase-3βbeta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer. Molecular cancer therapeutics 2003; 2: 1215-22.
312. Song L, Zhou T, Jope RS. Lithium facilitates apoptotic signaling induced by activation of the Fas death domain-containing receptor. BMC neuroscience 2004; 5: 20.
313. Vescovo G, Volterrani M, Zennaro R, et al. Apoptosis in the skeletal muscle of patients with heart failure: investigation of clinical and biochemical changes. Heart 2000; 84: 431-7.
314. Adams V, Jiang H, Yu J, et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. Journal of the American College of Cardiology 1999; 33: 959-65.
315. Lewis MI. Apoptosis as a potential mechanism of muscle cachexia in chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine 2002; 166: 434-6.
316. Gao Y, Ordas R, Klein JD, Price SR. Regulation of caspase-3 activity by insulin in skeletal muscle cells involves both PI3-kinase and MEK-1/2. Journal of applied physiology 2008; 105: 1772-8.
317. Kuemmerle JF. Endogenous IGF-I protects human intestinal smooth muscle cells from apoptosis by regulation of GSK-3β beta activity. American journal of physiology. Gastrointestinal and liver physiology 2005; 288: G101-10.
318. Musaro A, Giacinti C, Borsellino G, et al. Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1. Proceedings of the National Academy of Sciences of the United States of America 2004; 101: 1206-10.
319. Conboy IM, Conboy MJ, Smythe GM, Rando TA. Notch-mediated restoration of regenerative potential to aged muscle. Science 2003; 302: 1575-7.
320. Brack AS, Conboy IM, Conboy MJ, Shen J, Rando TA. A temporal switch from notch to Wnt signaling in muscle stem cells is necessary for normal adult myogenesis. Cell Stem Cell 2008; 2: 50-9.
321. Tsivitse S. Notch and Wnt signaling, physiological stimuli and postnatal myogenesis. Int J Biol Sci 2010; 6: 268-81.
322. Espinosa L, Ingles-Esteve J, Aguilera C, Bigas A. Phosphorylation by glycogen synthase kinase-3β beta down-regulates Notch activity, a link for Notch and Wnt pathways. J Biol Chem 2003; 278: 32227-35.
323. Guha S, Cullen JP, Morrow D, et al. Glycogen synthase kinase 3 beta positively regulates Notch signaling in vascular smooth muscle cells: role in cell proliferation and survival. Basic Res Cardiol 2011; 106: 773-85.
324. Cadigan KM, Nusse R. Wnt signaling: a common theme in animal development. Genes Dev 1997; 11: 3286-305.
325. Geetha-Loganathan P, Nimmagadda S, Scaal M. Wnt signaling in limb organogenesis. Organogenesis 2008; 4: 109-15.
326. Cossu G, Borello U. Wnt signaling and the activation of myogenesis in mammals. EMBO J 1999; 18: 6867-72.
327. Petropoulos H, Skerjanc IS. Beta-catenin is essential and sufficient for skeletal myogenesis in P19 cells. J Biol Chem 2002; 277: 15393-9.
328. Galli LM, Willert K, Nusse R, et al. A proliferative role for Wnt-3a in chick somites. Dev Biol 2004; 269: 489-504.
329. Otto A, Schmidt C, Luke G, et al. Canonical Wnt signalling induces satellite-cell proliferation during adult skeletal muscle regeneration. J Cell Sci 2008; 121: 2939-50.
330. Tajbakhsh S, Borello U, Vivarelli E, et al. Differential activation of Myf5 and MyoD by different Wnts in explants of mouse paraxial mesoderm and the later activation of myogenesis in the absence of Myf5. Development 1998; 125: 4155-62.
331. Berkes CA, Tapscott SJ. MyoD and the transcriptional control of myogenesis. Seminars in cell & developmental biology 2005; 16: 585-95.
332. Knight JD, Kothary R. The myogenic kinome: protein kinases critical to mammalian skeletal myogenesis. Skeletal muscle 2011; 1: 29.
333. Polesskaya A, Seale P, Rudnicki MA. Wnt signaling induces the myogenic specification of resident CD45+ adult stem cells during muscle regeneration. Cell 2003; 113: 841-52.
334. Armstrong DD, Wong VL, Esser KA. Expression of beta-catenin is necessary for physiological growth of adult skeletal muscle. Am J Physiol Cell Physiol 2006; 291: C185-8.
335. Descamps S, Arzouk H, Bacou F, et al. Inhibition of myoblast differentiation by Sfrp1 and Sfrp2. Cell Tissue Res 2008; 332: 299-306.
336. Pansters NA, van der Velden JL, Kelders MC, Laeremans H, Schols AM, Langen RC. Segregation of myoblast fusion and muscle-specific gene expression by distinct ligand-dependent inactivation of GSK-3βbeta. Cellular and molecular life sciences: CMLS 2011; 68: 523-35.
337. Peifer M, McCrea PD, Green KJ, Wieschaus E, Gumbiner BM. The vertebrate adhesive junction proteins beta-catenin and plakoglobin and the Drosophila segment polarity gene armadillo form a multigene family with similar properties. J Cell Biol 1992; 118: 681-91.
338. Wrobel E, Brzoska E, Moraczewski J. M-cadherin and beta-catenin participate in differentiation of rat satellite cells. Eur J Cell Biol 2007; 86: 99-109.
339. Kramerova I, Kudryashova E, Wu B, Spencer MJ. Regulation of the M-cadherin-beta-catenin complex by calpain 3 during terminal stages of myogenic differentiation. Mol Cell Biol 2006; 26: 8437-47.
340. Ishido M, Uda M, Masuhara M, Kami K. Alterations of Mcadherin, neural cell adhesion molecule and beta-catenin expression in satellite cells during overload-induced skeletal muscle hypertrophy. Acta Physiol (Oxf) 2006; 187: 407-18.
341. Mukai A, Kurisaki T, Sato SB, Kobayashi T, Kondoh G, Hashimoto N. Dynamic clustering and dispersion of lipid rafts contribute to fusion competence of myogenic cells. Experimental cell research 2009; 315: 3052-63.
342. Kishida M, Koyama S, Kishida S, et al. Axin prevents Wnt-3ainduced accumulation of beta-catenin. Oncogene 1999; 18: 979-85.
343. Zeman RJ, Bauman WA, Wen X, Ouyang N, Etlinger JD, Cardozo CP. Improved functional recovery with oxandrolone after spinal cord injury in rats. Neuroreport 2009; 20: 864-8.
344. Yamamoto H, Kishida S, Kishida M, Ikeda S, Takada S, Kikuchi A. Phosphorylation of axin, a Wnt signal negative regulator, by glycogen synthase kinase-3βbeta regulates its stability. J Biol Chem 1999; 274: 10681-4.
345. Shefer G, Benayahu D. The effect of exercise on IGF-I on muscle fibers and satellite cells. Front Biosci (Elite Ed) 2012; 4: 230-9.
346. van der Velden JL, Langen RC, Kelders MC, et al. Myogenic differentiation during regrowth of atrophied skeletal muscle is associated with inactivation of GSK-3βbeta. Am J Physiol Cell Physiol 2007; 292: C1636-44.
347. Schmid C, Steiner T, Froesch ER. Preferential enhancement of myoblast differentiation by insulin-like growth factors (IGF I and IGF II) in primary cultures of chicken embryonic cells. FEBS Lett 1983; 161: 117-21.
348. Florini JR, Ewton DZ, Falen SL, Van Wyk JJ. Biphasic concentration dependency of stimulation of myoblast differentiation by somatomedins. Am J Physiol 1986; 250: C771-8.
349. van der Velden JL, Schols AM, Willems J, Kelders MC, Langen RC. Glycogen synthase kinase 3 suppresses myogenic differentiation through negative regulation of NFATc3. The Journal of biological chemistry 2008; 283: 358-66.
350. Schulz RA, Yutzey KE. Calcineurin signaling and NFAT activation in cardiovascular and skeletal muscle development. Dev Biol 2004; 266: 1-16.
351. Delling U, Tureckova J, Lim HW, De Windt LJ, Rotwein P, Molkentin JD. A calcineurin-NFATc3-dependent pathway regulates skeletal muscle differentiation and slow myosin heavy-chain expression. Mol Cell Biol 2000; 20: 6600-11.
352. Chin ER, Olson EN, Richardson JA, et al. A calcineurin-dependent transcriptional pathway controls skeletal muscle fiber type. Genes Dev 1998; 12: 2499-509.
353. Miyazaki M, Hitomi Y, Kizaki T, et al. Calcineurin-mediated slowtype fiber expression and growth in reloading condition. Med Sci Sports Exerc 2006; 38: 1065-72.
354. Abbott KL, Friday BB, Thaloor D, Murphy TJ, Pavlath GK. Activation and cellular localization of the cyclosporine A-sensitive transcription factor NF-AT in skeletal muscle cells. Mol Biol Cell 1998; 9: 2905-16.
355. Beals CR, Sheridan CM, Turck CW, Gardner P, Crabtree GR. Nuclear export of NF-ATc enhanced by glycogen synthase kinase3. Science 1997; 275: 1930-4.
356. Shanely RA, Zwetsloot KA, Childs TE, Lees SJ, Tsika RW, Booth FW. IGF-I activates the mouse type IIb myosin heavy chain gene. Am J Physiol Cell Physiol 2009.
357. Aschenbach WG, Ho RC, Sakamoto K, et al. Regulation of dishevelled and beta-catenin in rat skeletal muscle: an alternative exercise-induced GSK-3βbeta signaling pathway. Am J Physiol Endocrinol Metab 2006; 291: E152-8.
358. Ding VW, Chen RH, McCormick F. Differential regulation of glycogen synthase kinase 3beta by insulin and Wnt signaling. J Biol Chem 2000; 275: 32475-81.
359. Wagman AS, Johnson KW, Bussiere DE. Discovery and development of GSK3 inhibitors for the treatment of type 2 diabetes. Curr Pharm Des 2004; 10: 1105-37.
360. Cline GW, Johnson K, Regittnig W, et al. Effects of a novel glycogen synthase kinase-3β inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. Diabetes 2002; 51: 2903-10.
361. Del Ser T, Steinwachs KC, Gertz HJ, et al. Treatment of Alzheimer's Disease with the GSK-3β Inhibitor Tideglusib: A Pilot Study. J Alzheimers Dis 2012.
362. Dominguez JM, Fuertes A, Orozco L, del Monte-Millan M, Delgado E, Medina M. Evidence for irreversible inhibition of glycogen synthase kinase-3βbeta by tideglusib. J Biol Chem 2012; 287: 893-904.
363. Marsell R, Sisask G, Nilsson Y, et al. GSK-3β inhibition by an orally active small molecule increases bone mass in rats. Bone 2012; 50: 619-27.
364. Clement-Lacroix P, Ai M, Morvan F, et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A 2005; 102: 17406-11.
365. Adamowicz K, Wang H, Jotwani R, Zeller I, Potempa J, Scott D. Inhibition of GSK3 abolishes bacterial-induced periodontal bone loss in mice. Mol Med 2012.
366. Koh SH, Kim Y, Kim HY, Hwang S, Lee CH, Kim SH. Inhibition of glycogen synthase kinase-3β suppresses the onset of symptoms and disease progression of G93A-SOD1 mouse model of ALS. Exp Neurol 2007; 205: 336-46.
367. Koh SH, Baek W, Kim SH. Brief review of the role of glycogen synthase kinase-3βbeta in amyotrophic lateral sclerosis. Neurol Res Int 2011; 2011: 205761.
368. Chen PC, Gaisina IN, El-Khodor BF, et al. Identification of a Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3β) Inhibitor, BIP-135, that Prolongs the Median Survival Time of Delta7 SMA KO Mouse Model of Spinal Muscular Atrophy. ACS Chem Neurosci 2012; 3: 5-11.
369. Doucet M, Russell AP, Leger B, et al. Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 261-9.
370. Leger B, Senese R, Al-Khodairy AW, et al. Atrogin-1, MuRF1, and FoXO, as well as phosphorylated GSK-3βbeta and 4E-BP1 are reduced in skeletal muscle of chronic spinal cord-injured patients. Muscle Nerve 2009; 40: 69-78.
371. Aversa Z, Bonetto A, Penna F, et al. Changes in myostatin signaling in non-weight-losing cancer patients. Ann Surg Oncol 2012; 19: 1350-6.
372. Caron MA, Charette SJ, Maltais F, Debigare R. Variability of protein level and phosphorylation status caused by biopsy protocol design in human skeletal muscle analyses. BMC Res Notes 2011; 4: 488.
373. Crul T, Testelmans D, Spruit MA, et al. Gene expression profiling in vastus lateralis muscle during an acute exacerbation of COPD. Cell Physiol Biochem 2010; 25: 491-500.
374. Wilson C, Hargreaves M, Howlett KF. Exercise does not alter subcellular localization, but increases phosphorylation of insulinsignaling proteins in human skeletal muscle. Am J Physiol Endocrinol Metab 2006; 290: E341-6.
375. Leger B, Cartoni R, Praz M, et al. Akt signalling through GSK3beta, mTOR and Foxo1 is involved in human skeletal muscle hypertrophy and atrophy. J Physiol 2006; 576: 923-33.
376. Sakamoto K, Arnolds DE, Ekberg I, Thorell A, Goodyear LJ. Exercise regulates Akt and glycogen synthase kinase-3β activities in human skeletal muscle. Biochem Biophys Res Commun 2004; 319: 419-25.
377. Freland L, Beaulieu JM. Inhibition of GSK3 by lithium, from single molecules to signaling networks. Front Mol Neurosci 2012; 5: 14.
378. Wojtaszewski JF, Hansen BF, Gade, Kiens B, Markuns JF, Goodyear LJ, Richter EA. Insulin signaling and insulin sensitivity after exercise in human skeletal muscle. Diabetes 2000; 49: 325-31.
379. Medina M, Castro A. Glycogen synthase kinase-3β (GSK-3β) inhibitors reach the clinic. Curr Opin Drug Discov Devel 2008; 11: 533-43.
380. Martinez A. Preclinical efficacy on GSK-3β inhibitors: towards a future generation of powerful drugs. Med Res Rev 2008; 28: 773-96.